Vice President at Merck Biopharma and Head of Department Innovation and Entrepreneurship Incubator. I hold a diploma in biochemistry and physiologic
chemistry from the University of Tübingen
and a Ph.D. in Genetics from
the University of Cologne. I am author
of more than 70 publications and patents (incl. papers in Cell, Nature Biotechnology and Nature Medicine). I am married and have three children.
Key Business Accomplishments
Prevymis (Letermovir), the anti-HCMV drug I am co-inventor of has received U.S. FDA approval in 2018..
Initiator and manager Curious2018-Future InSight Conference (http://curious2018.com)
Pritelivir, the anti-HSV drug I am co-inventor of has successfully passed Phase 2 clinical trials in 2017.
R&D Manager of the year 2017
Gold Stevie Award Winner
Edison Award 2017
Letermovir, the anti-HCMV drug I am co-inventor of has successfully passed Phase 3 clinical trials in 2016.
German Industry Innovation Award 2015 for innovative HR concepts
Appointed reviewer for the German Ministry of Education and Research (BMBF)
Established "Innovation Boost" as new corporate online ideation module using modern social media
Publication in Nature Biotechnology (2015)
German Idea Award 2014 - best international idea
Designed new Outcubator Concept and realized it with BioMed X in Heidelberg (2013)
Publication in Cell (2012)
Knowledge Management Bio IT World Best Practice Award 2012
Top 1% most viewed linked-in profiles in 2012
Enabled dozens of innovation projects for new products with business potential of several hundred million euros in an innovation incubator, first product launch 2012 CellVento, second product wins CPhI Best Innovation Award 2012 - product launch 2013 Parteck SLC, third product launch 2014 MyMeds
Invented and rolled-out the Merck Serono Innovation Cup bringing young talent and experienced retirees together to generate breakthrough innovation in diverse teams
Designed and rolled-out company wide new innovation initiative innospire for global idea sourcing and enablement in an entrepreneurial setting, with direct sponsorship from the Merck board and CEO
Design and management of cross-divisional innovation seed fund to support cross-divisional collaboration between Merck Serono and Merck Millipore after acquisition of Millipore by Merck
Built-up the Center of Innovation at Merck Serono, appointed as Director and Head of Department
Built-up the Strategic Innovation & Research Portfolio Management Department at Merck Serono, appointed as Director and Head of Department
Post merger integration after acquisition of Serono by Merck, design of the new drug discovery process and governance structure
Contributed to innovation integration subcommittee during acquisition of Millipore by Merck
Defined the preclinical R&D Asia strategy and execution via a number of key business deals
Key contributions to change management in Pharma Research at Bayer during a process of intense global restructuring
Publication in Nature Medicine (2002)
Initiated, established and chaired the Pharma Research Europe Award at Bayer
Essential contribution to identification of compound class that led to HCMV inhibitor Letermovir, which in the meantime has successfully passed phase III clinical trials.
Essential contribution to identification of HSV inhibitor Pritelivir currently in phase II clinical trials.
Publication in Cell (1999)
Dr. rer. nat. ("mit Auszeichnung")
Generated and characterized a conditional gp130 knock-out mouse line and a cre-transgenic mouse line
Dipl. Biochem. ("sehr gut")
Identified and characterized the MHC Class I of the Coelacanth living fossil Latimeria Chalumnae
I was awarded a scholarship of the German National Academic Foundation,
“Studienstiftung des deutschen Volkes”